Cardio Diagnostics received $225K in National Institutes of Health (NIH) funding to further develop our integrated genetic-epigenetic coronary heart disease risk screening technology.
Cardio Diagnostics receives a Phase I NIH SBIR
Cardio Diagnostics received $225K in National Institutes of Health (NIH) funding to further develop our integrated genetic-epigenetic coronary heart disease risk screening technology.